Clinical relevance of molecular aberrations in paediatric acute myeloid leukaemia at first relapse

British Journal of Haematology

Volumn 166, Issue 6, 2014, Pages 902-910

  Bachas, Costa ^a   Schuurhuis, Gerrit Jan ^a   Reinhardt, Dirk ^b   Creutzig, Ursula ^b   Kwidama, Zinia J ^a   Zwaan, C Michel ^c   van den Heuvel Eibrink, Marry M ^c   De Bont, Evelina S J M ^d   Elitzur, Sarah ^e   Rizzari, Carmelo ^f   de Haas, Valérie ^g   Zimmermann, Martin ^b   Cloos, Jacqueline ^a   Kaspers, Gertjan J L ^a,g  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b HANNOVER MEDICAL SCHOOL   (Germany)

^c SOPHIA CHILDREN S HOSPITAL   (Netherlands)

^d UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^e SCHNEIDER CHILDREN S MEDICAL CENTER OF ISRAEL   (Israel)

^f UNIVERSITY OF MILANO BICOCCA   (Italy)

^g DUTCH CHILDHOOD ONCOLOGY GROUP   (Netherlands)

Author keywords

Acute myeloid leukaemia; Event free survival; Mutation analysis; Overall survival; Relapse

Indexed keywords

ANTHRACYCLINE DERIVATIVE; CYTARABINE; FLUDARABINE; GRANULOCYTE COLONY STIMULATING FACTOR;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ARTICLE; CANCER PROGNOSIS; CHILD; CHILDHOOD LEUKEMIA; CHROMOSOME BANDING PATTERN; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG MEGADOSE; FEMALE; FLT3 GENE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE; GENE MUTATION; GENETIC ANALYSIS; HUMAN; KARYOTYPE; KIT GENE; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; MAJOR CLINICAL STUDY; MALE; NPM1 GENE; NUCLEOTIDE SEQUENCE; ONCOGENE K RAS; ONCOGENE N RAS; OVERALL SURVIVAL; PRESCHOOL CHILD; PRIORITY JOURNAL; RECURRENCE FREE SURVIVAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RISK FACTOR; TANDEM REPEAT; WT1 GENE; YOUNG ADULT;

ACUTE MYELOID LEUKAEMIA; EVENT FREE SURVIVAL; MUTATION ANALYSIS; OVERALL SURVIVAL; RELAPSE;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; DISEASE-FREE SURVIVAL; FEMALE; GENES, NEOPLASM; HUMANS; INFANT; KARYOTYPE; LEUKEMIA, MYELOID, ACUTE; MALE; MUTATION; NEOPLASM PROTEINS; RECURRENCE; RISK FACTORS;

EID: 84907597184     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.12989     Document Type: Article

References (40)

1. Abrahamsson, J., Clausen, N., Gustafsson, G., Hovi, L., Jonmundsson, G., Zeller, B., Forestier, E., Heldrup, J. & Hasle, H. (2007) Improved outcome after relapse in children with acute myeloid leukaemia. British Journal of Haematology, 136, 229-236.
2. Anguille, S., Van Tendeloo, V.F. & Berneman, Z.N. (2012) Leukemia-associated antigens and their relevance to the immunotherapy of acute myeloid leukemia. Leukemia, 26, 2186-2196.
3. Bachas, C., Schuurhuis, G.J., Hollink, I.H.I.M., Kwidama, Z.J., Goemans, B.F., Zwaan, C.M., van den Heuvel-Eibrink, M.M., de Bont, E.S.J.M., Reinhardt, D., Creutzig, U., de Haas, V., Assaraf, Y.G., Kaspers, G.J.L. & Cloos, J. (2010) High-frequency type I/II mutational shifts between diagnosis and relapse are associated with outcome in pediatric AML: implications for personalized medicine. Blood, 116, 2752-2758.
4. Balgobind, B.V., Hollink, I.H.I.M., Arentsen-Peters, S.T.C.J.M., Zimmermann, M., Harbott, J., Beverloo, H.B., von Bergh, A.R.M., Cloos, J., Kaspers, G.J.L., de Haas, V., Zemanova, Z., Stary, J., Cayuela, J.-M., Baruchel, A., Creutzig, U., Reinhardt, D., Pieters, R., Zwaan, C.M. & van den Heuvel-Eibrink, M.M. (2011) Integrative analysis of type-I and type-II aberrations underscores the genetic heterogeneity of pediatric acute myeloid leukemia. Haematologica, 96, 1478-1487.
5. Breems, D.A., Van Putten, W.L.J., Huijgens, P.C., Ossenkoppele, G.J., Verhoef, G.E.G., Verdonck, L.F., Vellenga, E., De Greef, G.E., Jacky, E., Van der Lelie, J., Boogaerts, M.A. & Löwenberg, B. (2005) Prognostic index for adult patients with acute myeloid leukemia in first relapse. Journal of Clinical Oncology, 23, 1969-1978.
6. Brown, P. & Smith, F.O. (2008) Molecularly targeted therapies for pediatric acute myeloid leukemia: progress to date. Paediatric Drugs, 10, 85-92.
7. Chevallier, P., Labopin, M., Turlure, P., Prebet, T., Pigneux, A., Hunault, M., Filanovsky, K., Cornillet-Lefebvre, P., Luquet, I., Lode, L., Richebourg, S., Blanchet, O., Gachard, N., Vey, N., Ifrah, N., Milpied, N., Harousseau, J.-L., Bene, M.-C., Mohty, M. & Delaunay, J. (2011) A new Leukemia Prognostic Scoring System for refractory/relapsed adult acute myelogeneous leukaemia patients: a GOELAMS study. Leukemia, 25, 939-944.
8. Cloos, J., Goemans, B.F., Hess, C.J., van Oostveen, J.W., Waisfisz, Q., Corthals, S., de Lange, D., Boeckx, N., Hählen, K., Reinhardt, D., Creutzig, U., Schuurhuis, G.J., Zwaan, C.M. & Kaspers, G.J.L. (2006) Stability and prognostic influence of FLT3 mutations in paired initial and relapsed AML samples. Leukemia, 20, 1217-1220.
9. Creutzig, U., van den Heuvel-Eibrink, M.M., Gibson, B., Dworzak, M.N., Adachi, S., de Bont, E., Harbott, J., Hasle, H., Johnston, D., Kinoshita, A., Lehrnbecher, T., Leverger, G., Mejstrikova, E., Meshinchi, S., Pession, A., Raimondi, S.C., Sung, L., Stary, J., Zwaan, C.M., Kaspers, G.J.L. & Reinhardt, D. (2012) Diagnosis and management of acute myeloid leukemia in children and adolescents: recommendations from an international expert panel. Blood, 120, 3187-3205.
10. Falini, B., Martelli, M.P., Bolli, N., Sportoletti, P., Liso, A., Tiacci, E. & Haferlach, T. (2011) Acute myeloid leukemia with mutated nucleophosmin (NPM1): is it a distinct entity? Blood, 117, 1109-1120.
11. Harrison, C.J., Hills, R.K., Moorman, A.V., Grimwade, D.J., Hann, I., Webb, D.K.H., Wheatley, K., de Graaf, S.S.N., van den Berg, E., Burnett, A.K. & Gibson, B.E.S. (2010) Cytogenetics of childhood acute myeloid leukemia: United Kingdom Medical Research Council Treatment trials AML 10 and 12. Journal of Clinical Oncology, 28, 2674-2681.
12. Ho, P.A., Kutny, M.A., Alonzo, T.A., Gerbing, R.B., Joaquin, J., Raimondi, S.C., Gamis, A.S. & Meshinchi, S. (2011) Leukemic mutations in the methylation-associated genes DNMT3A and IDH2 are rare events in pediatric AML: a report from the Children's Oncology Group. Pediatric Blood & Cancer, 57, 204-209.
13. Hollink, I.H.I.M., Zwaan, C.M., Zimmermann, M., Arentsen-Peters, T.C.J.M., Pieters, R., Cloos, J., Kaspers, G.J.L., de Graaf, S.S.N., Harbott, J., Creutzig, U., Reinhardt, D., van den Heuvel-Eibrink, M.M. & Thiede, C. (2009a) Favorable prognostic impact of NPM1 gene mutations in childhood acute myeloid leukemia, with emphasis on cytogenetically normal AML. Leukemia, 23, 262-270.
14. Hollink, I.H.I.M., van den Heuvel-Eibrink, M.M., Zimmermann, M., Balgobind, B.V., Arentsen-Peters, S.T.C.J.M., Alders, M., Willasch, A., Kaspers, G.J.L., Trka, J., Baruchel, A., de Graaf, S.S.N., Creutzig, U., Pieters, R., Reinhardt, D. & Zwaan, C.M. (2009b) Clinical relevance of Wilms tumor 1 gene mutations in childhood acute myeloid leukemia. Blood, 113, 5951-5960.
15. Kaspers, G.J.L. (2012) Pediatric acute myeloid leukemia. Expert Review of Anticancer Therapy, 12, 405-413.
16. Kaspers, G.J.L. (2014) How I treat paediatric relapsed AML. British Journal of Haematology in press, doi: 10.1111/bjh.12947.
17. Kaspers, G.J.L. & Zwaan, C.M. (2007) Pediatric acute myeloid leukemia: towards high-quality cure of all patients. Haematologica, 92, 1519-1532.
18. Kaspers, G.J.L., Zimmermann, M., Reinhardt, D., Gibson, B.E.S., Tamminga, R.Y.J., Aleinikova, O., Armendariz, H., Dworzak, M., Ha, S.-Y., Hasle, H., Hovi, L., Maschan, A., Bertrand, Y., Leverger, G.G., Razzouk, B.I., Rizzari, C., Smisek, P., Smith, O., Stark, B. & Creutzig, U. (2013) Improved outcome in pediatric relapsed acute myeloid leukemia: results of a randomized trial on liposomal daunorubicin by the International BFM Study Group. Journal of Clinical Oncology, 31, 599-607.
19. Kelly, L.M., Liu, Q., Kutok, J.L., Williams, I.R., Boulton, C.L. & Gilliland, D.G. (2002) FLT3 internal tandem duplication mutations associated with human acute myeloid leukemias induce myeloproliferative disease in a murine bone marrow transplant model. Blood, 99, 310-318.
20. Kiyoi, H., Naoe, T., Nakano, Y., Yokota, S., Minami, S., Miyawaki, S., Asou, N., Kuriyama, K., Jinnai, I., Shimazaki, C., Akiyama, H., Saito, K., Oh, H., Motoji, T., Omoto, E., Saito, H., Ohno, R. & Ueda, R. (1999) Prognostic implication of FLT3 and N-RAS gene mutations in acute myeloid leukemia. Blood, 93, 3074-3080.
21. Kottaridis, P.D., Gale, R.E., Frew, M.E., Harrison, G., Langabeer, S.E., Belton, A.A., Walker, H., Wheatley, K., Bowen, D.T., Burnett, A.K., Goldstone, A.H. & Linch, D.C. (2001) The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United King. Blood, 98, 1752-1759.
22. Meshinchi, S., Woods, W.G., Stirewalt, D.L., Sweetser, D.A., Buckley, J.D., Tjoa, T.K., Bernstein, I.D. & Radich, J.P. (2001) Prevalence and prognostic significance of Flt3 internal tandem duplication in pediatric acute myeloid leukemia. Blood, 97, 89-94.
23. Pollard, J.A., Alonzo, T.A., Gerbing, R.B., Ho, P.A., Zeng, R., Ravindranath, Y., Dahl, G., Lacayo, N.J., Becton, D., Chang, M., Weinstein, H.J., Hirsch, B., Raimondi, S.C., Heerema, N.A., Woods, W.G., Lange, B.J., Hurwitz, C., Arceci, R.J., Radich, J.P., Bernstein, I.D., Heinrich, M.C. & Meshinchi, S. (2010) Prevalence and prognostic significance of KIT mutations in pediatric patients with core binding factor AML enrolled on serial pediatric cooperative trials for de novo AML. Blood, 115, 2372-2379.
24. Pui, C.-H., Carroll, W.L., Meshinchi, S. & Arceci, R.J. (2011) Biology, risk stratification, and therapy of pediatric acute leukemias: an update. Journal of Clinical Oncology, 29, 551-565.
25. Renneville, A., Roumier, C., Biggio, V., Nibourel, O., Boissel, N., Fenaux, P. & Preudhomme, C. (2008) Cooperating gene mutations in acute myeloid leukemia: a review of the literature. Leukemia, 22, 915-931.
26. Rubnitz, J.E., Razzouk, B.I., Lensing, S., Pounds, S., Pui, C.-H. & Ribeiro, R.C. (2007) Prognostic factors and outcome of recurrence in childhood acute myeloid leukemia. Cancer, 109, 157-163.
27. Rücker, F.G., Schlenk, R.F., Bullinger, L., Kayser, S., Teleanu, V., Kett, H., Habdank, M., Kugler, C.-M., Holzmann, K., Gaidzik, V.I., Paschka, P., Held, G., von Lilienfeld-Toal, M., Lübbert, M., Fröhling, S., Zenz, T., Krauter, J., Schlegelberger, B., Ganser, A., Lichter, P., Döhner, K. & Döhner, H. (2012) TP53 alterations in acute myeloid leukemia with complex karyotype correlate with specific copy number alterations, monosomal karyotype, and dismal outcome. Blood, 119, 2114-2121.
28. Sander, A., Zimmermann, M., Dworzak, M., Fleischhack, G., von Neuhoff, C., Reinhardt, D., Kaspers, G.J.L. & Creutzig, U. (2010) Consequent and intensified relapse therapy improved survival in pediatric AML: results of relapse treatment in 379 patients of three consecutive AML-BFM trials. Leukemia, 24, 1422-1428.
29. Schnittger, S., Eder, C., Jeromin, S., Alpermann, T., Fasan, A., Grossmann, V., Kohlmann, A., Illig, T., Klopp, N., Wichmann, H.-E., Kreuzer, K., Schmid, C., Staib, P., Peceny, R., Schmitz, N., Kern, W., Haferlach, C. & Haferlach, T. (2013) ASXL1 exon 12 mutations are frequent in AML with intermediate risk karyotype and are independently associated with an adverse outcome. Leukemia, 27, 82-91.
30. Scrucca, L., Santucci, A. & Aversa, F. (2007) Competing risk analysis using R: an easy guide for clinicians. Bone Marrow Transplantation, 40, 381-387.
31. Smith, C.C., Wang, Q., Chin, C.-S., Salerno, S., Damon, L.E., Levis, M.J., Perl, A.E., Travers, K.J., Wang, S., Hunt, J.P., Zarrinkar, P.P., Schadt, E.E., Kasarskis, A., Kuriyan, J. & Shah, N.P. (2012) Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia. Nature, 485, 260-263.
32. Staffas, A., Kanduri, M., Hovland, R., Rosenquist, R., Ommen, H.B., Abrahamsson, J., Forestier, E., Jahnukainen, K., Jónsson, Ó.G., Zeller, B., Palle, J., Lönnerholm, G., Hasle, H., Palmqvist, L. & Ehrencrona, H. (2011) Presence of FLT3-ITD and high BAALC expression are independent prognostic markers in childhood acute myeloid leukemia. Blood, 118, 5905-5913.
33. Stahnke, K., Boos, J., Bender-Götze, C., Ritter, J., Zimmermann, M. & Creutzig, U. (1998) Duration of first remission predicts remission rates and long-term survival in children with relapsed acute myelogenous leukemia. Leukemia, 12, 1534-1538.
34. Steelman, L.S., Franklin, R.A., Abrams, S.L., Chappell, W., Kempf, C.R., Bäsecke, J., Stivala, F., Donia, M., Fagone, P., Nicoletti, F., Libra, M., Ruvolo, P., Ruvolo, V., Evangelisti, C., Martelli, A.M. & McCubrey, J.A. (2011) Roles of the Ras/Raf/MEK/ERK pathway in leukemia therapy. Leukemia, 25, 1080-1094.
35. Thiede, C., Steudel, C., Mohr, B., Schaich, M., Schäkel, U., Platzbecker, U., Wermke, M., Bornhäuser, M., Ritter, M., Neubauer, A., Ehninger, G. & Illmer, T. (2002) Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis. Blood, 99, 4326-4335.
36. Vardiman, J.W., Thiele, J., Arber, D.A., Brunning, R.D., Borowitz, M.J., Porwit, A., Harris, N.L., Le Beau, M.M., Hellström-Lindberg, E., Tefferi, A. & Bloomfield, C.D. (2009) The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood, 114, 937-951.
37. Von Neuhoff, C., Reinhardt, D., Sander, A., Zimmermann, M., Bradtke, J., Betts, D.R., Zemanova, Z., Stary, J., Bourquin, J.-P., Haas, O.A., Dworzak, M.N. & Creutzig, U. (2010) Prognostic impact of specific chromosomal aberrations in a large group of pediatric patients with acute myeloid leukemia treated uniformly according to trial AML-BFM 98. Journal of Clinical Oncology, 28, 2682-2689.
38. Webb, D.K. (1999) Management of relapsed acute myeloid leukaemia. British Journal of Haematology, 106, 851-859.
39. Webb, D.K., Wheatley, K., Harrison, G., Stevens, R.F. & Hann, I.M. (1999) Outcome for children with relapsed acute myeloid leukaemia following initial therapy in the Medical Research Council (MRC) AML 10 trial. MRC Childhood Leukaemia Working Party. Leukemia, 13, 25-31.
40. Weltermann, A., Fonatsch, C., Haas, O.A., Greinix, H.T., Kahls, P., Mitterbauer, G., Jäger, U., Kainz, B., Geissler, K., Valent, P., Sperr, W.R., Knöbl, P., Schwarzinger, I., Gleiss, A. & Lechner, K. (2004) Impact of cytogenetics on the prognosis of adults with de novo AML in first relapse. Leukemia, 18, 293-302.